Next Article in Journal
Recall of Reverberant Speech in Quiet and Four-Talker Babble Noise
Previous Article in Journal
Effect of Xenon Treatment on Gene Expression in Brain Tissue after Traumatic Brain Injury in Rats
Previous Article in Special Issue
Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
Article

Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study

1
Multiple Sclerosis Center “A. Cardarelli” Hospital, 80131 Naples, Italy
2
Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy
3
Regional Center of Pharmacovigilance and Pharmacoepidemiology of Campania Region, 80138 Naples, Italy
4
Neurological Clinic and Stroke Unit “A. Cardarelli” Hospital, 80131 Naples, Italy
*
Author to whom correspondence should be addressed.
These authors share first authorship.
These authors are both lead authors.
Academic Editors: John Matsoukas and Vasso Apostolopoulos
Received: 4 June 2021 / Revised: 1 July 2021 / Accepted: 3 July 2021 / Published: 5 July 2021
(This article belongs to the Special Issue Advances in Multiple Sclerosis Research—Series II)
Background. The so-called “vaccine hesitancy” still represents a common phenomenon that undermines the effectiveness of vaccination campaigns. In 2020, the Italian Medicines Agency recommended to bring forward the flu vaccination campaign, whose importance was also emphasized for patients with Multiple Sclerosis (MS). We aimed to assess vaccination behavior in patients with MS to prepare for the upcoming SARS-CoV-2 vaccination challenge. Methods. This is an observational study carried out in one MS clinical Centre that enrolled all MS patients who were eligible for any of the flu vaccines recommended by the Italian medicines Agency. Results. 194 patients were enrolled. Patients’ mean age was 43.9 years and 66% were female. Comorbidities, mainly represented by non-autoimmune diseases, were identified in 52% of patients. Almost all patients were receiving a DMT during the study period, mainly dimethyl fumarate, natalizumab, teriflunomide, and interferon. Out of 194 patients, 58.2% accepted to be vaccinated. No statistically significant differences were found, except for the use of natalizumab, which was higher among vaccinated patients. Conclusion. The results of our study emphasize the importance of education and communication campaigns addressed both to healthcare providers and patients with MS, especially considering that MS patients are currently receiving COVID-19 vaccinations. View Full-Text
Keywords: influenza vaccine; hesitancy; multiple sclerosis; observational study influenza vaccine; hesitancy; multiple sclerosis; observational study
MDPI and ACS Style

Ziello, A.; Scavone, C.; Di Battista, M.E.; Salvatore, S.; Di Giulio Cesare, D.; Moreggia, O.; Allegorico, L.; Sagnelli, A.; Barbato, S.; Manzo, V.; Capuano, A.; Maniscalco, G.T. Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study. Brain Sci. 2021, 11, 890. https://0-doi-org.brum.beds.ac.uk/10.3390/brainsci11070890

AMA Style

Ziello A, Scavone C, Di Battista ME, Salvatore S, Di Giulio Cesare D, Moreggia O, Allegorico L, Sagnelli A, Barbato S, Manzo V, Capuano A, Maniscalco GT. Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study. Brain Sciences. 2021; 11(7):890. https://0-doi-org.brum.beds.ac.uk/10.3390/brainsci11070890

Chicago/Turabian Style

Ziello, Antonio, Cristina Scavone, Maria E. Di Battista, Simona Salvatore, Daniele Di Giulio Cesare, Ornella Moreggia, Lia Allegorico, Anna Sagnelli, Stefano Barbato, Valentino Manzo, Annalisa Capuano, and Giorgia T. Maniscalco 2021. "Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study" Brain Sciences 11, no. 7: 890. https://0-doi-org.brum.beds.ac.uk/10.3390/brainsci11070890

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop